S26 Using clinical trial data to tailor adjuvant treatments for individual patients

Using clinical trial data to tailor adju

Using clinical trial data to tailor adjuvant treatments for individual patients

✍ Meredith M. Regan; Richard D. Gelber 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 178 KB

Modifying Clinical Trial Designs to Test

Modifying Clinical Trial Designs to Test Treatments for Clinical Significance in Individual Patients

✍ Dr Robert E. Becker 📂 Article 📅 2001 🏛 Springer International Publishing AG 🌐 English ⚖ 104 KB

Use of luteinising-hormone-releasing hor

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials

📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 341 KB

Use of luteinising-hormone-releasing hor

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials

✍ Fleming, G.F.; Francis, P. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 65 KB

Intent-to-treat analysis for clinical tr

Intent-to-treat analysis for clinical trials: use of data collected after termination of treatment protocol

✍ Sati Mazumdar; Patricia R Houck; Kenneth S Liu; Benoit H Mulsant; Bruce G Polloc 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 290 KB

Donepezil for the symptomatic treatment

Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials

✍ Anne Whitehead; Carlos Perdomo; Raymond D. Pratt; Jacqueline Birks; Gordon K. Wi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 3 views

## Abstract ## Background The objective was to evaluate the efficacy and tolerability of donepezil (5 and 10 mg/day) compared with placebo in alleviating manifestations of mild to moderate Alzheimer's disease (AD). ## Method A systematic review of individual patient data from Phase II and III do